Corrigendum: Swanson MA, Coughlin CR Jr, Scharer GH, et al: Biochemical and Molecular Predictors for Prognosis in Nonketotic Hyperglycinemia. *Ann Neurol* 2015;78:606–618.

In this study, we expressed 27 missense mutations in *GLDC* and measured residual enzyme activity and protein levels. We recently identified in the expression vector for the mutant c.1705G>A, p.A569T, a second, off-target, unintended mutation that had escaped sequencing verification of the vector. Repeat expression study with a corrected vector showed that this mutation has $77 \pm 1.5\%$ residual activity, and normal protein levels. In addition, the presence of this mutation in homozygous form in 4 subjects without nonketotic hyperglycinemia in the Exome Aggregation Consortium database confirms that this sequence variant should be reclassified as a polymorphism and is not disease-causing.^{1–3} This new information does not change the other findings or the conclusions in the article.

Potential Conflicts of Interest

Nothing to report.

Michael A. Swanson, PhD
Curtis R. Coughlin Jr, MS, MBE
Johan L. K. Van Hove, MD, PhD

Department of Pediatrics
University of Colorado
Aurora, CO

References

1. bioRxiv. Analysis of protein-coding genetic variation in 60,706 humans. Available at: <http://biorxiv.org/content/early/2015/10/30/030338>.
2. Exome Aggregation Consortium. ExAC browser (beta). Available at: <http://exac.broadinstitute.org>. Accessed December 2015.
3. Richards S, Aziz N, Bale S, et al; American College of Medical Genetics Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405–424.

DOI: 10.1002/ana.24600